Bacil Pharma

Bacil Pharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Bacil Pharma (524516.BO) as of Oct 30, 2026 is 77.50. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 130.88 — a change of -40.78% (lower).

EV/FCF

77.50

YoY

-40.78%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Bacil Pharma is 2026 77.50 . EV/FCF (Enterprise Value to Free Cash Flow) of Bacil Pharma was 2025 130.88 . It decreases by -40.78% lower compared to the previous year.

The Bacil Pharma EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
38.49 INR
Jan 1, 2020
-145.80 INR
Jan 1, 2021
-138.56 INR
Jan 1, 2022
-13.76 INR
Jan 1, 2023
-372.59 INR
Jan 1, 2024
-19,037.57 INR
Jan 1, 2025
130.88 INR
Jan 1, 2026
77.50 INR
The Bacil Pharma EV/FCF history
YEAREV/FCFYoY
77.50-40.78%
130.88-100.69%
-19,037.57+5,009.59%
-372.59+2,608.29%
-13.76-90.07%
-138.56-4.96%
-145.80-478.75%
38.49-20.84%
48.63-100.74%
-6,547.32+61,112.70%
-10.70-104.70%
227.64-121.55%
-1,056.34—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bacil Pharma Stock analysis

What does Bacil Pharma do? Bacil Pharma Ltd, identified by the ticker symbol 524516.BO and the ISIN INE711D01018, is a prominent entity within the Indian healthcare sector. Headquartered in Mumbai, Maharashtra, the company has established itself as a significant player in the pharmaceutical industry. Bacil Pharma Ltd specializes in the comprehensive manufacturing and distribution of a diverse range of products, including pharmaceuticals, medicinal chemicals, and botanical products. This strategic focus on both synthetic medicinal compounds and natural botanical ingredients allows the company to cater to a broad spectrum of therapeutic needs and market demands. The firm's operational base in Mumbai, one of India's major financial and commercial hubs, provides it with substantial logistical advantages and access to a well-developed infrastructure network, which is crucial for the timely distribution of healthcare products across the country and potentially into international markets. The company's journey in the public domain began with its initial public offering on March 15, 1994. This milestone marked a significant step in its corporate evolution, enabling it to raise capital for expansion, research, and development activities. Since its listing, Bacil Pharma Ltd has continued to refine its product portfolio and manufacturing capabilities, maintaining a steady presence in the competitive pharmaceutical landscape. The company's official website, http://www.bacilpharma.com/, serves as a primary resource for stakeholders, investors, and customers seeking detailed information about its product lines, corporate governance, and business operations. By engaging in the manufacture and sale of both medicinal and botanical products, Bacil Pharma Ltd demonstrates a commitment to integrating traditional herbal wisdom with modern pharmaceutical science. This dual approach not only reflects the growing global interest in natural health solutions but also positions the company to capitalize on emerging trends in preventive healthcare and wellness. As a listed entity on the Indian stock exchange, Bacil Pharma Ltd is subject to regulatory oversight and disclosure requirements, ensuring transparency and accountability to its shareholders. The company's enduring presence in the market since the mid-1990s underscores its resilience and adaptability in a dynamic industry characterized by rapid technological advancements and evolving regulatory frameworks. Through its continued focus on quality manufacturing and product innovation, Bacil Pharma Ltd aims to sustain its growth trajectory and contribute to the broader healthcare ecosystem in India and beyond. Bacil Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bacil Pharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of Bacil Pharma is 77.50 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Bacil Pharma changed from 130.88 to 77.50, representing a -40.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Bacil Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Bacil Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bacil Pharma

All Key Metrics — Bacil Pharma